期刊文献+

沙格列汀与二甲双胍治疗体质量超重的初诊2型糖尿病的疗效比较 被引量:9

原文传递
导出
摘要 目的比较沙格列汀与二甲双胍治疗体质量超重的初诊2型糖尿病患者的疗效。方法选取合并体质量超重的初诊2型糖尿病患者124例,分别在生活方式干预基础上给予常规沙格列汀与二甲双胍治疗,随访12周,检测治疗前后血压、血糖、糖化血红蛋白、血脂、胰岛素等指标,并进行组间比较,分析两种治疗方案的差异。结果两种药物治疗前后,血糖均有明显下降,差异有统计学意义(P〈0.05);沙格列汀组空腹血糖与糖化血红蛋白下降程度与二甲双胍组相当(P〉0.05),沙格列汀组餐后血糖低于二甲双胍组,差异有统计学意义(P〈0.05),两组患者血压、血脂等指标均较治疗前有所好转,但组间差异无统计学意义(P〉0.05)。结论对于合并超重、初诊的2型糖尿病患者,给予沙格列汀和二甲双胍治疗效果相当。
作者 张明涛
出处 《中国实用医刊》 2014年第8期118-119,共2页 Chinese Journal of Practical Medicine
  • 相关文献

参考文献7

二级参考文献65

  • 1Azuma K, Rodikova Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab, 2008,93:459-464.
  • 2Drucker DJ,Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet ,2006,368 : 1696-1705.
  • 3Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept,2005,128 : 125-134.
  • 4Ayala JE, Bracy DP, Hansotia T, et al. Insulin action in the double incretin receptor knockout mouse. Diabetes, 2008, 57: 288 -297.
  • 5Ahren B,Hughes TE. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate eyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology, 2005, 146: 2055 -2059.
  • 6Green BD, Irwin N, Flatt PR, et al. Pituitary adenylate cyclase-activating peptide (PACAP) :assessment of dipeptidyl peptidase Ⅳ degradation, insulin-releasing activity and antidiabetic potential Peptides, 2006,27 : 1349 - 1358.
  • 7Lamont B J, Drueker DJ. Differential antidiabetic effieacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes,2008,57 : 190-198.
  • 8Kuo LE ,Kitlinska JB ,Tilan .IU ,et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obcsit3, and metabolic syndrome. Nat Med,2007,13 : 803-811.
  • 9Green BD, Flatt PR, Bailey C J, et al. Dipeptidyl peptidase Ⅳ (DPP Ⅳ) inhibitors:A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Bes,2006,3 : 159-165.
  • 10Pospisilik jA, Martin J, Doty T,et al. Dipeptidyl peptidase Ⅳ inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes, 2003, 52: 741-750.

共引文献61

同被引文献73

引证文献9

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部